Scott Wasserman, Amgen Inc.'s vice president of global development, told BioWorld Today that a new, 5,000-patient observational study will "cast a more focused light on the unmet need" in knocking down levels of low-density lipoprotein cholesterol (LDL-C), as researchers will take "multiple snapshots" over a three-year period. "It's meant to help the medical community get a pulse on how we're doing in terms of treating these high-risk patients," he said.